Polo-like Kinase 1 Inhibition in <i>KRAS</i>-Mutated Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer

Published:2024-03-12 Issue:10 Volume:30 Page:2005-2007
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Stebbing Justin¹^ORCID,Bullock Andrea J.²^ORCID

Affiliation:

1. 1Department of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom.

2. 2Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Abstract

Summary: Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-0251/3422812/ccr-24-0251.pdf

Reference15 articles.

1. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase 1b clinical study;Ahn;Clin Cancer Res,2024

2. Plk1 overexpression induces chromosomal instability and suppresses tumor development;de Cárcer;Nat Commun,2018

3. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis;Gelot;Nature,2023

4. Present and future perspective on PLK1 inhibition in cancer treatment;Chiappa;Front Oncol,2022

5. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells;Han;Med Sci Monit,2012